The FDA has taken Evofem Biosciences to task for allegedly playing fast and loose with the facts, accusing the biotech of overstating the benefits of its contraceptive Phexxi in a digital patient brochure.
Evofem Biosciences last week received an untitled letter from the FDA, which cited “misleading” benefits in a marketing brochure for its contraceptive gel brand Phexxi.
SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the second quarter and first half of 2023.
SAN DIEGO, June 16, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced financial results for the first quarter of 2023, including growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).
SAN DIEGO, June 1, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced strong preliminary results for the first quarter of 2023, including robust growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).